Biomatics Capital

Biomatics Capital Partners is a U.S. life-sciences and healthcare venture capital firm headquartered in Seattle, Washington, founded in 2016 by Co-Founders and Managing Directors Dr. Boris Nikolic (Harvard-trained physician with immunology background; science advisor to Bill Gates and Bill & Melinda Gates Foundation's bgc3 / Gates Ventures / Gates Frontier; previously led the Editas Medicine USD 120 million CRISPR round) and Julie Sunderland (previously head of the Bill & Melinda Gates Foundation's Strategic Investment Fund). The firm invests at the intersection of healthcare and technology across genomics, digital health, data-driven healthcare, therapeutics, diagnostics, clinical-care platforms, and R&D technology. Biomatics has raised multiple institutional funds: Fund I closed at USD 200 million (2017, exceeding a USD 150 million target) and Fund II at USD 300 million (2018), with aggregate AUM in the USD low-billions range, investing from Seed through Pre-IPO with check sizes typically in the USD 1 to 50 million range. LPs include family offices, institutional investors, and individuals. Notable portfolio companies include GRAIL (cancer-detection unicorn), Denali Therapeutics, Verana Health, Aledade, eGenesis (xenotransplantation), BlackThorn Therapeutics, Omniome, Twist Bioscience, AiCure, Verve Therapeutics, and Encodia, with 6 disclosed IPOs and multiple acquisitions from the portfolio.